SPECTRUM PHARMACEUTICALS INC SPPI Cash Flow

Spectrum pharmaceuticals inc (SPPI)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash Flows From Operating Activities:
Cash Flows From Operating Activities:
Loss from continuing operations
-136,157	-135,386	-148,415	-191,030	-147,380	-126,706	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income from discontinued operations, net of income taxes (Note 10)
2,155	22,697	24,931	24,813	23,196	5,965	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-134,002	-112,689	-123,484	-166,217	-124,184	-120,741	-100,290	-49,865	-84,458	-92,189	-81,391	-80,552	-83,996	-69,770	-57,080	-58,350	-36,401	-52,642	-49,608	-42,423	-43,640	-45,719	-82,115	-78,181	-84,340	-62,134	-15,272	14,432	42,224	94,201	96,406	94,562	83,696	49,931	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,400	14,375	16,450	18,546	12,300	12,300	12,300	12,300	12,300	0	0	0
Depreciation and amortization
429	1,620	8,896	15,816	22,745	28,409	28,007	28,004	27,985	27,972	27,964	27,973	27,466	26,492	30,127	30,220	30,860	31,869	27,895	27,302	26,389	25,352	24,539	23,503	22,730	22,096	21,778	18,972	15,921	12,243	8,373	7,213	6,166	5,650	0	0	0
Deferred income tax benefit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Stock-based compensation (Note 4)
19,113	21,838	21,491	21,291	21,005	17,483	18,135	17,143	15,897	15,139	14,117	14,273	14,213	13,670	15,205	14,555	14,656	13,941	11,710	12,274	11,700	11,809	12,350	12,277	12,247	12,423	14,122	14,458	14,616	14,884	16,445	17,454	21,188	22,237	0	0	0
Recognized gain on Commercial Product Portfolio Transaction (Note 10)
924	34,568	33,451	33,644	33,644	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of operating leases (Note 8(a))
0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of discount on investments in debt securities, recorded to interest income (Note 3(a))
234	205	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Realized gain on mutual funds
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of intangible assets (Note 3(g))
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,160	7,160	7,160	7,160	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of Allos deferred development costs and deferred payment contingency (Note 16)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Research and development expense recognized for the value of common stock issued in connection with QAPZOLA (Note 17(b)(x)) and ROLONTIS (Note 17(b)(xiii)) milestone achievements
-	-	-	-	-	-	-	-	-	-	-	-	-	2,419	2,419	2,419	111	0	0	0	0	7,790	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Income tax recognition on unrealized gain on available-for-sale securities
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss on CASI stock holdings (Note 3(a) and Note 7)
1,951	6	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for inventory obsolescence
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Unrealized gain from transactions denominated in foreign currency
1,490	1,469	-9	-16	-38	-31	5,202	5,212	5,234	5,237	16	171	178	153	747	4,146	1,271	157	-1,999	-9,419	-7,525	-6,033	-5,016	-1,174	101	-1,222	0	0	0	-	-	-	-	-	-	-	-
Change in deferred tax liabilities
2,947	1,478	-3,405	-3,405	-3,405	-1,927	4,812	4,839	4,892	4,957	90	-28	-100	-104	81	77	41	210	-334	-1,020	-1,318	-602	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss (gain) on marketable securities (Note 3(a))
-	-	-	-	-	-	-	-	10,196	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of contingent consideration (Note 8(b))
-1,478	0	4,126	2,926	3,118	1,931	937	5,079	4,984	4,890	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of deferred financing costs on 2018 Convertible Notes, recorded to interest expense (Note 9)
-	-	-	-	-	220	-2,111	-1,148	-281	567	5,700	5,704	5,706	5,710	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bad debt expense (recovery)
-	-	-	-	-	-	-	-	-	-	-	-	-	57	-26	-15	-60	0	-28	-57	29	-85	22	55	34	127	3	-53	-163	-128	-16	-77	198	245	0	0	0
Research and development expense for the value of stock issued to TopoTarget in connection with milestone achievement (Note 13)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Change in fair value of common stock warrants issued to non-employees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,488	0	0	0
Accretion of debt discount, recorded to interest expense on 2018 Convertible Notes (Note 14)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Write off of Deferred Debt Issuance Cost
-	-	-	-	-	-	0	0	462	-	666	672	691	696	690	680	671	662	649	618	630	599	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in cash surrender value of corporate-owned life insurance policy
-	-	-	-	-	-	-	-	-	418	403	290	241	137	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable, net
-14,506	-29,420	-28,951	-25,071	-18,341	-2,844	-8,803	-14,886	-6,801	-7,694	-4,689	7,695	20,370	9,494	-5,668	-7,375	-49,567	-40,245	-11,422	-14,526	15,353	21,671	5,184	4,418	14,630	-42,559	-36,017	-39,347	-22,966	33,504	36,327	38,291	3,581	30,897	0	0	0
Other receivables
1,333	5,871	2,637	7,325	4,585	1,571	-749	-1,583	-3,091	-3,663	-1,236	-2,506	-9,205	-6,895	-6,562	-1,428	7,118	7,017	4,129	-3,576	-318	-2,070	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Inventories
0	2,037	1,509	-537	-696	-3,390	-6,626	-4,706	-6,179	-4,318	-1,522	694	4,263	5,800	7,032	3,213	999	-1,863	-2,804	-2,013	-3,774	-4,253	-4,699	-5,042	-4,310	-1,570	-4,469	-57	425	-3,530	969	-1,276	2,327	6,528	0	0	0
Prepaid expenses and other assets
3,945	2,473	6,285	7,973	5,264	3,642	9,471	4,531	4,207	6,137	255	1,415	1,373	423	-491	1,032	-272	446	-441	-618	-14,202	718	-1,542	-5,135	14,016	359	3,687	-4,742	-9,230	-9,483	-2,546	8,077	7,797	7,115	0	0	0
Deferred tax assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-56	-1,415	-1,491	-1,724	-44,789	-39,363	-38,562	-33,252	0	0	0	-	-	-	-	-	-	-	-
Other assets
-615	1,188	1,308	-472	-5,723	-5,010	-6,280	-4,161	1,436	-1,573	-235	-194	-97	2,043	2,428	114	2,151	1,731	756	14,279	12,704	13,161	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and other accrued liabilities
-25,537	-35,769	-22,768	-13,116	5,168	12,112	8,956	-5,270	3,521	6,459	-392	7,839	772	-4,033	-29,255	-23,599	-34,594	-28,298	-22,298	2,911	10,950	5,304	24,171	-23,061	-17,721	-23,897	-28,684	-23,866	7,591	24,038	35,979	44,443	21,820	15,711	0	0	0
Accrued payroll and benefits
-601	-2,168	-1,269	314	1,767	592	106	-1,297	-1,773	280	-102	-250	624	790	602	715	182	-233	317	672	2	1,594	-908	-826	-924	425	-8,898	-11,915	-12,074	-9,726	-1,354	689	767	-1,525	0	0	0
FOLOTYN development liability
0	-4	-123	-198	-290	-389	-310	-372	-488	-744	-1,734	-1,820	-1,740	-1,556	-241	-107	-609	-1,100	-2,002	-2,699	-2,387	-1,957	-6,396	-4,119	-4,223	-5,917	769	-908	-632	2,376	-195	2,389	2,570	3,519	0	0	0
Other long-term liabilities
-130	3,047	1,888	1,743	135	-564	-5,130	-4,700	-3,334	-3,389	2,355	1,790	1,764	2,153	1,802	1,660	1,159	1,355	1,177	1,285	1,521	124	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	487	-2,985	-5,287	-3,363	-14,834	-3,511	359	7,395	17,056	9,803	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue and other credits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Net cash used in operating activities
-127,919	-134,631	-115,749	-99,505	-75,713	-62,403	-62,991	-58,648	-45,473	-38,855	-29,322	-35,770	-53,503	-40,459	-33,993	-30,387	4,948	6,744	14,659	33,691	31,075	-3,627	-6,723	-29,860	-63,718	-2,086	-1,909	30,454	66,696	71,959	74,825	75,945	86,545	43,288	0	0	0
Purchase of equity securities (Note 10)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash Flows From Investing Activities:
Cash Flows From Investing Activities:
Proceeds from Commercial Product Portfolio Transaction (Note 1(b))
-194	158,571	158,765	158,765	158,765	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from maturities of marketable securities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of mutual funds
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales and maturities of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	72,463	67,499	60,895	14,691	18,255	0	0	0
Purchases of investment securities available-for-sale (Note 3(a))
209,158	200,160	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26,430	21,445	12,999	12,415	17,027	0	0	0
Purchases of mutual funds
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment (Note 3(b))
10,099	9,018	8,731	1,302	369	107	99	344	381	465	429	184	153	78	72	72	206	223	338	541	692	934	842	639	437	161	135	137	264	312	399	436	387	475	0	0	0
Proceeds from redemption of corporate-owned life insurance policy
-	-	-	-	-	4,130	4,130	4,130	4,130	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Redemption of mutual funds
-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,712	0	0	0	-	-	-	-
Net cash provided by investing activities
-87,096	31,992	63,414	32,323	155,747	1,373	4,017	3,772	3,133	-1,081	-1,631	-1,386	-737	-679	-73	2,988	2,837	2,838	-22,277	-21,613	-21,599	-21,841	3,271	-11,643	-14,606	-14,330	-13,305	-137,311	-115,590	-114,690	-114,599	21,396	1,260	746	0	0	0
Cash Flows From Financing Activities:
Cash Flows From Financing Activities:
Proceeds from employees for exercises of stock options
6,316	7,147	11,987	12,525	12,386	13,475	10,269	9,271	7,312	5,477	3,064	1,025	237	203	190	674	1,129	1,482	1,928	1,563	1,069	1,906	2,066	3,778	3,865	3,576	4,195	4,431	5,715	5,817	0	0	0	-	-	-	-
Proceeds from employees, for our remittance to tax authorities, upon vesting of restricted stock
-	-	-	-	-	4,645	4,645	4,645	4,645	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments to tax authorities upon employees' surrender of restricted stock upon vesting and upon exercises of stock options
-	-	-	-	-	27,679	30,541	30,733	31,144	4,331	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock from stock option exercises
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Purchase of treasury stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,651	1,761	10,392	10,392	9,057	0	0	0	-	-	-	-
Purchase and retirement of restricted stock to satisfy employees' tax liability at vesting
-	-	-	-	-	-	-	-	-	-	-	-	-	-	838	788	768	638	1,678	1,658	1,995	1,733	1,581	1,689	1,125	1,509	1,554	1,518	2,137	1,434	0	0	0	-	-	-	-
Repayment of capital leases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	17	25	33	31	0	0	0
Proceeds from revolving line of credit (Note 14)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100,000	0	0	0	-	-	-	-	-	-	-	-
Repayment of revolving line of credit (Note 14)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	175,000	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
8,796	9,627	14,623	15,158	13,495	-8,457	-21,690	91,086	88,388	108,721	106,684	19,509	59,197	59,644	69,190	40,922	988	1,471	876	531	-287	812	78,479	55,083	37,583	35,258	-54,864	37,873	59,532	61,025	72,636	25,679	22,746	23,611	0	0	0
Effect of exchange rates on cash and equivalents
-81	-50	-191	-76	-390	-356	-263	-152	269	316	132	201	-67	-25	-46	-35	168	-1,254	-965	-2,743	-3,558	-1,708	-2,768	-2,279	-1,599	-2,235	0	0	0	-	-	-	-	-	-	-	-
Net increase in cash, cash equivalents and restricted cash
-206,300	-93,062	-37,903	-52,100	93,139	-69,843	-80,927	36,058	46,317	69,101	75,863	-17,446	4,890	18,481	35,078	13,488	8,941	9,799	-7,707	9,866	5,631	-26,364	72,260	11,302	-42,339	16,608	-71,309	-69,051	10,700	18,496	32,990	123,105	110,551	67,645	0	0	0
Targent milestones included in intangible assets and accrued liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Noncash investing activities:
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,652	0	0	0	-	-	-	-	-	-	-	-
Supplemental disclosure of cash flow information:
Cash paid for facility and equipment under operating leases
1,957	1,835	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for income taxes
5	38	45	51	78	45	45	34	17	17	10	10	2	11	14	14	13	335	332	332	660	329	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
C-E MELPHALAN license included in intangible assets and other long term obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	2,692	3,163	3,163	3,300	3,300	3,300	3,300	3,300	3,300	3,289	3,289	3,227	3,227	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Noncash investing activities:
Additions of property and equipment that remain in accounts payable and other accrued liabilities (Note 3(b))
0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion of preferred stock to common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	37	0	0	0